In addition, high numbers of peripheral CD8+ T-cells expressing differentiation markers and lacking CCR7 are associated with response to nivolumab in NSCLC patients [43] whereas the presence of CD8+CCR7+ T-cells in the peripheral blood has been demonstrated to associate with disease recurrences in patients with head and neck cancers [44]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.